The development of direct-acting antiviral therapies is a major advance in HCV treatment and numerous agents are in various stages of clinical development. With this rapidly changing landscape in HCV therapy, the potential of drug–drug interactions is an important aspect of management. Here, the pharmacokinetic interactions of current and investigational agents for hepatitis C are discussed.
- Jennifer J. Kiser
- James R. Burton Jr
- Gregory T. Everson
